Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), ...
Oclaiz is a subcutaneous long-acting octreotid depot, designed for optimized disease control and convenient self-administration. The product is based on Camurus' FluidCrystal technology and is ...
Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.
Crinetics Pharmaceuticals shares gained after the company reported positive results from its Phase 2 study of atumelnant as a treatment for congenital adrenal hyperplasia. The stock was up 9.4% to $51 ...
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December ...
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with ...
BioNTech SE ("BioNTech"), and OUP (Osage University Partners) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund ("PxB Fund"), a dedicated venture capital fund ...
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) shares rallied 19% after the company reported a strong early commercial ...
Stocktwits on MSN
CRNX stock gains, NBIX shares drop on positive results from genetics disorder trial
The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback